These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16355035)

  • 1. Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results.
    Bertolotto M; Pozzato G; Crocè LS; Nascimben F; Gasparini C; Cova MA; Tiribelli C
    Invest Radiol; 2006 Jan; 41(1):15-21. PubMed ID: 16355035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
    Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
    Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization.
    Ippolito D; Sironi S; Pozzi M; Antolini L; Ratti L; Alberzoni C; Leone EB; Meloni F; Valsecchi MG; Fazio F
    Acad Radiol; 2008 Jul; 15(7):919-27. PubMed ID: 18572129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.
    Liang PC; Ch'ang HJ; Hsu C; Chen LT; Shih TT; Liu TW
    Hepatol Int; 2015 Apr; 9(2):258-68. PubMed ID: 25788178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience.
    Petralia G; Fazio N; Bonello L; D'Andrea G; Radice D; Bellomi M
    J Comput Assist Tomogr; 2011; 35(2):195-201. PubMed ID: 21412089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image fusion of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) using volume navigation for detection, characterization and planning of therapeutic interventions of liver tumors.
    Rennert J; Georgieva M; Schreyer AG; Jung W; Ross C; Stroszczynski C; Jung EM
    Clin Hemorheol Microcirc; 2011; 49(1-4):67-81. PubMed ID: 22214679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced ultrasound of hepatocellular carcinoma: Correlation of washout time and angiogenesis.
    Xia Y; Jiang YX; Dai Q; Xiao Y; Lv K; Wang L
    Clin Hemorheol Microcirc; 2011; 48(4):265-73. PubMed ID: 22012832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
    Zhou JH; Cao LH; Liu JB; Zheng W; Liu M; Luo RZ; Han F; Li AH
    Radiology; 2011 May; 259(2):406-13. PubMed ID: 21292869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
    Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
    AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment.
    Zhou JH; Zheng W; Cao LH; Liu M; Luo RZ; Han F; Wu PH; Li AH
    Eur J Radiol; 2012 Jun; 81(6):1360-5. PubMed ID: 21345633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma.
    Wang Z; Liu G; Lu MD; Xie X; Kuang M; Wang W; Xu Z; Lin M; Chen L
    Ultrasound Med Biol; 2015 May; 41(5):1277-86. PubMed ID: 25623820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma.
    Maruyama H; Takahashi M; Ishibashi H; Okabe S; Yoshikawa M; Yokosuka O
    Eur J Radiol; 2010 Jul; 75(1):e102-6. PubMed ID: 19783392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced ultrasound (DCE-US) for easy and rapid evaluation of hepatocellular carcinoma compared to dynamic contrast-enhanced computed tomography (DCE-CT)--a pilot study.
    Egger C; Goertz RS; Strobel D; Lell M; Neurath MF; Knieling F; Scharf M
    Ultraschall Med; 2012 Dec; 33(6):587-92. PubMed ID: 23154871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiquantitative characterization of hepatocellular carcinoma (HCC)--perfusion with contrast-enhanced ultrasound and perfusion analysis.
    Schacherer D; Girlich C; Wiest R; Büttner R; Schölmerich J; Feuerbach S; Zorger N; Hamer OW; Jung EM
    Clin Hemorheol Microcirc; 2010; 44(2):97-105. PubMed ID: 20203364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-enhanced ultrasound improves real-time imaging of ablation region during radiofrequency ablation: preliminary results.
    Wiggermann P; Zuber-Jerger I; Zausig Y; Loss M; Scherer MN; Schreyer AG; Stroszczynski C; Jung EM
    Clin Hemorheol Microcirc; 2011; 49(1-4):43-54. PubMed ID: 22214677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy.
    Averkiou M; Lampaskis M; Kyriakopoulou K; Skarlos D; Klouvas G; Strouthos C; Leen E
    Ultrasound Med Biol; 2010 Jan; 36(1):68-77. PubMed ID: 19900749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.
    Quaia E; Calliada F; Bertolotto M; Rossi S; Garioni L; Rosa L; Pozzi-Mucelli R
    Radiology; 2004 Aug; 232(2):420-30. PubMed ID: 15286314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma.
    Hayano K; Lee SH; Yoshida H; Zhu AX; Sahani DV
    Acad Radiol; 2014 May; 21(5):654-60. PubMed ID: 24703479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.